An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 35, Issue 5, 2002, Pages 477-481

  De Azeredo Coutinho, Rilza Beatriz G ^a   Mendonça, Sergio C F ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

American cutaneous leishmaniasis; Antimonial therapy; Leishmania braziliensis

Indexed keywords

ANTIMONY DERIVATIVE; MEGLUMINE ANTIMONATE; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; SKIN LEISHMANIASIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; NONPARAMETRIC TEST; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

LEISHMANIA BRAZILIENSIS;

ADULT; ANTIPROTOZOAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0036452223     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822002000500009     Document Type: Article

References (29)

1. Anabwani GM, Nigra JA, Dimiti G, Bryceson ADM. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. Lancet 1: 210-213, 1983.
2. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Reviews of Infectious Diseases 10: 560-586, 1988.
3. Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. American Journal of Tropical Medicine and Hygiene 31: 459-465, 1982.
4. Chulay JD, Anzeze EM, Kohch DK, Bryceson ADM. High and low sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene 77: 717-721, 1983.
5. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Transactions of the Royal Society of Tropical Medicine and Hygiene 82: 69-72, 1988.
6. Cupolillo E, Grimaldi Jr G, Momen H. A general classification of New World Leishmania using numerical zymotaxonomy. American Journal of Tropical Medicine and Hygiene 50: 296-311, 1994.
7. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clinical Infectious Diseases 18: 83-90, 1994.
8. Goodwin LG, Page JE. A study of the excretion of organic antimonials using a polarographic procedure. Biochemical Journal 22: 236-240, 1943.
9. Grimaldi Jr G, David JR, McMahon-Pratt D. Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. American Journal of Tropical Medicine and Hygiene 36: 270-287, 1987.
10. Grimaldi Jr G, Tesh RB. Leishmaniasis of the New World: Current concepts and implications for future research. Clinical and Microbiology Reviews 6: 230-250, 1993.
11. Grögl M, Oduola AMJ, Cordere LDC, Kyle DE. Leishmania spp: Development of pentostam-resistant clones in vitro by discontinuous drug exposure. Experimental Parasitology 69: 78-90, 1989.
12. Guderian RH, Chico ME, Rogers MD, Pattishai KM, Grögl M, Berman JD. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 45: 92-97, 1991.
13. Guimarães MC, Celeste BJ, Franco EL. Diagnostic performance indices for immunofluorescence and enzyme immunoassays of leishmaniasis sera from northern and north-eastern Brazil. Bulletin of the World Health Organization 68: 39-43, 1990.
14. Llanos-Cuentas EA, Marsden PD, Lago EL, Barreto AC, Cuba CC, Johnson WD. Human mucocutaneous leishmaniasis in Três Braços, Bahia - Brazil. An area of Leishmania braziliensis braziliensis transmission. II. Cutaneous disease. Presentation and evolution. Revista da Sociedade Brasileira de Medicina Tropical 17: 169-177, 1984.
15. Lopes UG, Momen H, Grimaldi G Jr, Marzochi MCA, Pacheco R, Morel CM. Schizodeme and zymodeme characterization of Leishmania in the investigation of foci of visceral and cutaneous leishmaniasis. Journal of Parasitology 70: 89-98, 1984.
16. Manson-Bahr PEC 1959. East African kala-azar with special reference to the pathology, prophylaxis and treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 53: 123-37, 1959.
17. Marsden PD. New light on pentavalent antimonials in the treatment of leishmaniasis. Revista do Instituto de Medicina Tropical de São Paulo 16: 172-174, 1983.
18. Marsden PD. Pentavalent antimonials: Old drugs for new diseases. Revista da Sociedade Brasileira de Medicina Tropical 18: 187-198, 1985.
19. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Transactions of the Royal Society of Tropical Medicine and Hygiene 80: 859-876, 1986.
20. Mendonça SC, Coutinho SG, Amendoeira RR, Marzochi MCA, Pirmez C. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: Lymphoproliferative responses and influence of therapy. Clinical Experimental Immunology 64: 269- 276, 1986.
21. Mendonça SCF, Souza WJS, Nunes MP, Marzochi MCA, Coutinho SG. Indirect immunofluorescence test in New World leishmaniasis: Serological and clinical relationship. Memórias do Instituto Oswaldo Cruz 83: 347-355, 1988.
22. Mottram JC, Coombs GH. Leishmania mexicana: Enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Experimental Parasitology 59: 235-242, 1985.
23. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 165: 528-534, 1992.
24. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years). American Journal of Tropical Medicine and Hygiene 57: 651-655, 1997.
25. Roberts WL, Berman JD, Rainey PM. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrobial Agents and Chemotherapy 39: 1234-1239, 1995.
26. Roberts WL, Rainey PM. Antimony quantification of sodium stibogluconate fractions. Antimicrobial Agents and Chemotherapy 37: 1842-1846, 1993.
27. Tallab TM, Bahamdam KA, Mirdad S, Johargi H, Mourad MM, Ibrahim K, el Sherbini AH, Karkashan E, Khare AK, Jamal A. Cutaneous leishmaniasis: Schedules for intralesional treatment with sodium stibogluconate. International Journal of Dermatology 8: 594-597, 1996.
28. Wijers DJ. A 10-year study of kala-azar in Tharaka (Meru district, Kenya). II. Relapses. East African Medical Journal 48: 551-558, 1971.
29. Yarbuh AL, Anez N, Pena YP, Burguera JL, Burguera M. Antimony determination in tissues and serum of hamsters infected with meglumine antimoniate. Annals of Tropical Medicine and Parasitology 88: 37-41, 1994.